ENLIVEX THERAPEUTICS LTD ENLV 深 滬
交易中 10-30 11:56:29 美东时间
1.065
-0.005
-0.47%
華盛通- 最 高1.075
- 今 開1.07
- 成交量 2.87万股
- 最 低 1.0601
- 昨 收 1.07
- 總市值 2540.91万
- 52周最高 2.10
- 市盈率 靜 --
- 換手率 0.12%
- 52周最低 0.8101
- 委 比 -1.01%
- 總股本 2385.83万
- 歷史最高 44.90
- 量 比 0.43
- 振 幅 1.39%
- 歷史最低 0.8101
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
今天 14:22
Enlivex Therapeutics To Present Late-breaking Poster At ACR Convergence 2025 Featuring Phase IIa Topline Data For Allocetra In Patients With Moderate-To-Severe Knee Osteoarthritis. Data Showed Clinically Meaningful And Statistically Significant Improvements In Pain Reduction And Function Versus Placebo
Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of
10-28 20:19
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
Enlivex Therapeutics will present late-breaking Phase IIa clinical data for Allocetra™ in knee osteoarthritis at ACR Convergence 2025. The data show statistically significant improvement in pain and function in idiopathic age-related osteoarthritis patients. Professor Philip Conaghan will present the findings, including new biomarker data, on October 28. Enlivex is developing Allocetra™, an immunotherapy that reprograms macrophages, targeting lif...
10-28 12:15
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
Enlivex Therapeutics will participate in a webinar on September 30, 2025, discussing breakthroughs in knee osteoarthritis treatment. The webinar, hosted by D. Boral Capital, will feature leading experts and discuss positive Phase IIa data from Enlivex's Allocetra™ program, showing significant pain reduction and functional improvement in patients.
09-29 12:15
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.
09-12 20:00
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
Enlivex Therapeutics Ltd. reported promising Phase IIa results for Allocetra™ in knee osteoarthritis (KOA), showing significant pain reduction and functional improvement in older patients. The treatment was well-tolerated, with no serious adverse events. Key findings included a 72% reduction in pain and 109% improvement in function compared to placebo. Enlivex plans to release six-month data by November 2025 and initiate a Phase IIb trial in Q2 2...
09-11 12:00
Enlivex Secures Israeli Patent For Allocetra In Osteoarthritis Treatment, Extending IP Protection Through 2040
Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 290470, titled, "THERAPEUTIC
09-09 20:03
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
<p>Enlivex Therapeutics Ltd. has been granted an Israeli patent for using Allocetra™ to treat osteoarthritis, providing protection through at least 2040. The company reported positive Phase IIa data showing 24% knee pain reduction and 26% improvement in knee function with Allocetra™. CEO Oren Hershkovitz expressed confidence in securing similar patents globally. Osteoarthritis affects millions and has no approved treatments to slow joint damage, ...
09-09 12:00
HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $7 price target.
09-02 19:16
